Open AccessTherapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy
Author(s) -
Hisham Momattin,
Khurram Mohammed,
Alimuddin Zumla,
Ziad A. Memish,
Jaffar A. AlTawfiq
Publication year - 2013
Publication title -
international journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.278
H-Index - 89
eISSN - 1878-3511
pISSN - 1201-9712
DOI - 10.1016/j.ijid.2013.07.002
Subject(s) - middle east respiratory syndrome coronavirus , middle east respiratory syndrome , medicine , coronavirus , covid-19 , transmission (telecommunications) , intensive care medicine , betacoronavirus , severe acute respiratory syndrome coronavirus , virology , disease , infectious disease (medical specialty) , outbreak , engineering , electrical engineering
The Middle East Respiratory Syndrome coronavirus (MERS-CoV) has been detected in a number of countries in the Middle East and Europe with an apparently high mortality rate. It is phylogenetically related to the SARS coronavirus and has also been associated with severe respiratory illness as well as nosocomial transmission in healthcare settings. Current international recommendations do not support any specific therapies; however, there are a number of agents, which were used during the SARS epidemic of 2003. It is possible that these might be active against the related MERS coronavirus. We have reviewed the literature on the safety and efficacy of therapies used in patients with SARS with a view to their potential use in patients with MERS-CoV infections.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom